TD Waterhouse Canada’s Briacell Therapeutics BCTX Stock Holding History

TD Waterhouse Canada’s Portfolio BCTX Stock Details BCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$66	Hold	19	–	–	﹤0.01%	2334
2026 Q1	$78	Hold	19	–	–	﹤0.01%	2231
2025 Q4	$135	Hold	19	–	–	﹤0.01%	1954
2025 Q3	$238	Hold	19	–	–	﹤0.01%	1960
2025 Q2	$543	Hold	19	–	–	﹤0.01%	1851
2025 Q1	$659	Hold	19	–	–	﹤0.01%	1778
2024 Q4	$1.55K	Hold	19	–	–	﹤0.01%	1736
2024 Q3	$2.29K	Sell	19 -4	-17%	-$449	﹤0.01%	1617
2024 Q2	$3.69K	Sell	23 -57	-71%	-$16.1K	﹤0.01%	1547
2024 Q1	$41.4K	Hold	80	–	–	﹤0.01%	1094
2023 Q4	$76.4K	Hold	80	–	–	﹤0.01%	860
2023 Q3	$90.6K	Hold	80	–	–	﹤0.01%	786
2023 Q2	$90.3K	Buy	+80	New	+$79K	﹤0.01%	808

Other funds holding BCTX

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

SSA

SSA Swiss Advisors Zurich $266M AUM 24.57% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

HWA

HHM Wealth Advisors Chattanooga, Tennessee $996M AUM 23.11% 1-Year Est. Return

TD Waterhouse Canada's BCTX Position: Q2 2026 in Review

TD Waterhouse Canada held its Briacell Therapeutics (BCTX) position steady in Q2 2026 at 19 shares worth $66. The position accounts for ﹤0.01% of the portfolio, ranked #2334.

TD Waterhouse Canada first reported a position in BCTX in Q2 2023 and has held it in 13 quarters since. The position peaked at $90.6K in Q3 2023. 6 funds tracked by Wall St. Rank hold BCTX as of Q2 2026.

TD Waterhouse Canada held 19 shares of Briacell Therapeutics worth $66 as of Q2 2026.
TD Waterhouse Canada left its Briacell Therapeutics share count unchanged in Q2 2026.
Briacell Therapeutics made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #2334 holding.
TD Waterhouse Canada first reported a position in Briacell Therapeutics in Q2 2023 and has held it in 13 quarters since.
TD Waterhouse Canada's Briacell Therapeutics position peaked at $90.6K in Q3 2023.
6 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.